Trontinemab
Trontinemab (RG6102), Brainshuttle anti-amyloid antibody
Also known as: RG6102
Roche's anti-amyloid antibody with a transferrin-receptor 'shuttle' that cleared amyloid in 91% of patients within seven months at a fraction of the ARIA seen with lecanemab or donanemab; Phase 3 started in 2025.
Overview
Trontinemab fuses gantenerumab to a module that binds the transferrin receptor, ferrying the antibody across the blood-brain barrier at far lower doses. In Phase 1b/2a, 3.6 mg/kg produced amyloid-PET negativity in 91% of participants at 28 weeks with ARIA-E under 5%. The TRONTIER 1 and 2 Phase 3 trials began in September 2025 with an 18-month cognitive endpoint, and a prevention study was announced in 2026.
Mechanism of action
Anti-amyloid-beta antibody engineered for receptor-mediated transport across the blood-brain barrier, enabling rapid plaque removal at low systemic doses.
Key studies & citations
- Human2025
TRONTIER 1: trontinemab in early Alzheimer's disease
Phase 3 with 18-month CDR-SB primary endpoint.
ClinicalTrials.gov NCT07169578 - Human2025
Trontinemab Phase 1b/2a results
91% amyloid negativity at 28 weeks; ARIA-E under 5%.
PubMed Central PMC12741723 - Human2025
Roche presents trontinemab data at AAIC
Rapid, deep amyloid clearance with favorable safety.
Roche media release
Frequently asked questions
How is trontinemab different from lecanemab?
Both remove amyloid. Trontinemab's shuttle lets it enter the brain far more efficiently, so it clears plaque faster at lower doses and, so far, with much less ARIA swelling and bleeding.